Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial
R. Kendall (Vancouver, Canada), S. Shukla (Collegeville, United States of America), A. Martin (Uxbridge, United Kingdom), D. Shah (New York, United States of America), D. Midwinter (Brentford, United Kingdom), I. Boucot (Brentford, United Kingdom), N. Risebrough (Toronto, United States of America), P. Jones (Brentford, United Kingdom), C. Compton (Brentford, United Kingdom), A. Ismaila (Collegeville, United States of America)
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Session: Highlights for primary care in 2021
Session type: Oral Presentation
Number: 78
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Kendall (Vancouver, Canada), S. Shukla (Collegeville, United States of America), A. Martin (Uxbridge, United Kingdom), D. Shah (New York, United States of America), D. Midwinter (Brentford, United Kingdom), I. Boucot (Brentford, United Kingdom), N. Risebrough (Toronto, United States of America), P. Jones (Brentford, United Kingdom), C. Compton (Brentford, United Kingdom), A. Ismaila (Collegeville, United States of America). Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial. 78
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: